Differentiate Your Product From the Competition: Give Healthcare Decision Makers the Information They Need
In this competitive pharmaceutical market access landscape, payers are preparing budgets and financial forecasts well ahead of product launches, [...]
COVID-19 HEOR Researcher Discusses Pandemic Modeling
Models predicting the impact of pharmaceutical and non-pharmaceutical measures aimed at reducing the spread of COVID-19 have been developed throughout [...]
Biosimilar Market to Hit $178 Billion in 2024
In 2006, the European Medicines Agency approved its first biosimilar. Omnitrope was developed in cases of growth hormone deficiency. Now, [...]
ICER Announces Cloud-Based ICER Analytics Platform
The Institute for Clinical and Economic Review (ICER) has announced the launch of ICER Analytics. The new cloud-based tool is [...]
Xcenda Leader Provides Insight on Biosimilars for Payers and Pharma
Managing Director Allen Lising of Xcenda’s FormularyDecisions shared his thoughts on biosimilars. He notes that when it comes to the [...]
Payer Contact in a “Contactless” World: Achieving Early Engagement
The COVID-19 pandemic has prompted life sciences organizations to quickly pivot their payer strategic approach and tactical implementation. Engaging payers [...]
Payer Contact in a “Contactless” World: Achieving Early Engagement
In the first of a two-part series on early engagement with payers, Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Allen Lising, Managing Director of FormularyDecisions at Xcenda to discusss this innovative platform.
Study: ICER Reports Play Major Role in MCOs’ Decisions
Many managed care organizations say they use reports by the Institute for Clinical and Economic Review (ICER) in their decision-making, [...]
Xcenda Report Highlights Digital Health Tech, Gene Therapies for Hemophilia
Xcenda's latest HTA Quarterly report shifts the spotlight to digital health technology, gene therapies for hemophilia and the EU's new [...]
Xcenda Blog: Mind the (Evidence) Gap
Xcenda in a blog post considers how drug manufacturers can gather evidence to develop their value story before and after [...]
